522 related articles for article (PubMed ID: 28818333)
41. [Li-Fraumeni syndrome: update, new data and guidelines for clinical management].
Frebourg T; Abel A; Bonaiti-Pellie C; Brugières L; Berthet P; Bressac-de Paillerets B; Chevrier A; Chompret A; Cohen-Haguenauer O; Delattre O; Feingold J; Feunteun J; Frappaz D; Fricker JP; Gesta P; Jonveaux P; Kalifa C; Lasset C; Leheup B; Limacher JM; Longy M; Nogues C; Oppenheim D; Sommelet D; Soubrier F; Stoll C; Stoppa-Lyonnet D; Tristant H
Bull Cancer; 2001 Jun; 88(6):581-7. PubMed ID: 11459705
[TBL] [Abstract][Full Text] [Related]
42. EFGR-mutant lung adenocarcinoma and Li-Fraumeni syndrome: report of two cases and review of the literature.
Ricordel C; Labalette-Tiercin M; Lespagnol A; Kerjouan M; Dugast C; Mosser J; Desrues B; Léna H
Lung Cancer; 2015 Jan; 87(1):80-4. PubMed ID: 25433984
[TBL] [Abstract][Full Text] [Related]
43. p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies.
Pötzsch C; Voigtländer T; Lübbert M
J Cancer Res Clin Oncol; 2002 Aug; 128(8):456-60. PubMed ID: 12200603
[TBL] [Abstract][Full Text] [Related]
44. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium.
Mai PL; Malkin D; Garber JE; Schiffman JD; Weitzel JN; Strong LC; Wyss O; Locke L; Means V; Achatz MI; Hainaut P; Frebourg T; Evans DG; Bleiker E; Patenaude A; Schneider K; Wilfond B; Peters JA; Hwang PM; Ford J; Tabori U; Ognjanovic S; Dennis PA; Wentzensen IM; Greene MH; Fraumeni JF; Savage SA
Cancer Genet; 2012 Oct; 205(10):479-87. PubMed ID: 22939227
[TBL] [Abstract][Full Text] [Related]
45. A Japanese patient with Li-Fraumeni syndrome who had nine primary malignancies associated with a germline mutation of the p53 tumor-suppressor gene.
Izawa N; Matsumoto S; Manabe J; Tanizawa T; Hoshi M; Shigemitsu T; Machinami R; Kanda H; Takeuchi K; Miki Y; Arai M; Shirahama S; Kawaguchi N
Int J Clin Oncol; 2008 Feb; 13(1):78-82. PubMed ID: 18307025
[TBL] [Abstract][Full Text] [Related]
46. Late-onset common cancers in a kindred with an Arg213Gln TP53 germline mutation.
Ruijs MW; Verhoef S; Wigbout G; Pruntel R; Floore AN; de Jong D; van T Veer LJ; Menko FH
Fam Cancer; 2006; 5(2):169-74. PubMed ID: 16736287
[TBL] [Abstract][Full Text] [Related]
47. An update on the central nervous system manifestations of Li-Fraumeni syndrome.
Orr BA; Clay MR; Pinto EM; Kesserwan C
Acta Neuropathol; 2020 Apr; 139(4):669-687. PubMed ID: 31468188
[TBL] [Abstract][Full Text] [Related]
48. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
49. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
[TBL] [Abstract][Full Text] [Related]
50. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.
Olive KP; Tuveson DA; Ruhe ZC; Yin B; Willis NA; Bronson RT; Crowley D; Jacks T
Cell; 2004 Dec; 119(6):847-60. PubMed ID: 15607980
[TBL] [Abstract][Full Text] [Related]
51. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome.
Wong P; Verselis SJ; Garber JE; Schneider K; DiGianni L; Stockwell DH; Li FP; Syngal S
Gastroenterology; 2006 Jan; 130(1):73-9. PubMed ID: 16401470
[TBL] [Abstract][Full Text] [Related]
52. The evaluation of the possibility of Li-Fraumeni syndrome in cancer patients in East Azarbaijan Province of Iran.
Esmaeilzadeh Aghjeh M; Hosseinpour Feizi MA; Safaralizadeh R; Hosseinpour Feizi AA; Pouladi N
Nucleosides Nucleotides Nucleic Acids; 2024; 43(5):417-426. PubMed ID: 37801337
[TBL] [Abstract][Full Text] [Related]
53. Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.
Liu PK; Kraus E; Wu TA; Strong LC; Tainsky MA
Oncogene; 1996 Jun; 12(11):2267-78. PubMed ID: 8649766
[TBL] [Abstract][Full Text] [Related]
54. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome.
Wu CC; Shete S; Amos CI; Strong LC
Cancer Res; 2006 Aug; 66(16):8287-92. PubMed ID: 16912210
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
56. Cancer risks from germ line tumor suppressor gene mutations.
Frebourg T; Malkin D; Friend S
Princess Takamatsu Symp; 1991; 22():61-70. PubMed ID: 1844252
[TBL] [Abstract][Full Text] [Related]
57. Genetic modeling of Li-Fraumeni syndrome in zebrafish.
Parant JM; George SA; Holden JA; Yost HJ
Dis Model Mech; 2010; 3(1-2):45-56. PubMed ID: 20075382
[TBL] [Abstract][Full Text] [Related]
58. [Li Fraumeni syndrome: a case with multiple primary cancers and presenting a germline p53 mutation].
Landolsi S; Gharbi O; Zrig M; Gribaa M; Njim L; Zakhama A; Abid A; Frébourg T; Ahmed SB
Ann Biol Clin (Paris); 2010; 68(3):346-50. PubMed ID: 20478780
[TBL] [Abstract][Full Text] [Related]
59. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.
Ruijs MW; Schmidt MK; Nevanlinna H; Tommiska J; Aittomäki K; Pruntel R; Verhoef S; Van't Veer LJ
Eur J Hum Genet; 2007 Jan; 15(1):110-4. PubMed ID: 17003841
[TBL] [Abstract][Full Text] [Related]
60. Unaffected Li-Fraumeni Syndrome Carrier Parent Demonstrates Allele-Specific mRNA Stabilization of Wild-Type
Buzby JS; Williams SA; Nugent DJ
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
